Could 2 HPV vaccine doses be enough for women 27-45? new trial aims to find out.
NCT ID NCT05672927
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares the immune response from 2 doses versus the standard 3 doses of the HPV vaccine in women aged 27-45. About 618 participants will be randomly assigned to receive either 2 or 3 doses, and their antibody levels will be checked over 12 months. If 2 doses prove noninferior, it could lead to a simpler vaccination schedule for this age group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
9-valent HPV vaccine
What this could lead to
If 2 doses work as well as 3, it could simplify HPV vaccination for women in this age group, making it easier and cheaper to get protected.
What could go wrong
This is a Phase 4 study, but it only measures short-term antibody responses, not long-term cancer prevention. The results may not change current guidelines.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Texas Medical Branch
RECRUITINGGalveston, Texas, 77555, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••